Related Experiment Video
Updated: Mar 16, 2026
Mouse Model of Surgically-induced Endometriosis by Auto-transplantation of Uterine Tissue
Published on: January 6, 2012
Anti-platelet therapy is efficacious in treating endometriosis induced in mouse
Sun-Wei Guo1, Ding Ding2, Xishi Liu1
1Shanghai OB/GYN Hospital, Fudan University, Shanghai 200011, China; Shanghai Key Laboratory of Female Reproductive Endocrine-Related Diseases, Fudan University, Shanghai, China.
Abstract:
In light of recent findings showing that platelets play important roles in the development of endometriosis in general and in fibrogenesis in particular, this study investigated the efficacy of Ozagrel, a TXA2 synthase inhibitor, in a murine model of endometriosis. In addition, another mouse experiment was conducted to evaluate the effect of timing of platelet depletion and of sequential depletion of platelets and macrophages on the development of endometriosis. It was found that both the Ozagrel treatment and different platelet depletion schemes resulted in significant reduction in lesion growth (all P-values <0.01) along with improved hyperalgesia in mice with induced endometriosis. They also significantly reduced the expression of markers of proliferation, angiogenesis, inflammation and fibrosis as well as decreased macrophage infiltration in endometriotic lesions (all P-values <0.05). Compared with untreated mice, pre-emptive depletion of platelets as well as platelet depletion after induction resulted in significant reduction in lesion weight (both P-values <0.001), while sequential depletion of platelets and macrophages yielded similar reduction. These results, in conjunction with other roles that platelets play in the development of endometriosis, strongly argue for the potential of anti-platelet therapy in treating endometriosis.
Insights
Platelet inhibition with Ozagrel and platelet depletion strategies significantly reduced endometriosis lesion growth and pain in mice. These findings support anti-platelet therapy as a potential treatment for endometriosis.
Area of Science:
- Reproductive Biology
- Immunology
- Pharmacology
Background:
- Recent findings highlight the significant role of platelets in endometriosis development and fibrogenesis.
- Platelets are implicated in key pathological processes of endometriosis, including inflammation and fibrosis.
Purpose of the Study:
- To investigate the efficacy of Ozagrel, a thromboxane A2 (TXA2) synthase inhibitor, in a murine model of endometriosis.
- To evaluate the impact of platelet depletion timing and sequential depletion of platelets and macrophages on endometriosis progression.
Main Methods:
- Utilized a murine model of induced endometriosis.
- Administered Ozagrel (TXA2 synthase inhibitor) and implemented various platelet depletion protocols.
- Assessed lesion growth, hyperalgesia, and expression of proliferation, angiogenesis, inflammation, and fibrosis markers.
Main Results:
- Ozagrel treatment and platelet depletion significantly reduced endometriotic lesion growth and improved hyperalgesia (P<0.01).
- Both interventions decreased markers of proliferation, angiogenesis, inflammation, and fibrosis (P<0.05).
- Platelet depletion, both pre-emptive and post-induction, significantly reduced lesion weight (P<0.001), as did sequential depletion of platelets and macrophages.
Conclusions:
- Anti-platelet therapy, exemplified by Ozagrel, shows significant therapeutic potential for endometriosis.
- Targeting platelet activity and infiltration is a promising strategy for managing endometriosis, including its associated pain and fibrotic aspects.
